MedTrace Logo

Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19

NCT04530578 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-08-31

No results posted yet for this study

Summary

To evaluate the safety and efficacy of the use of inhalational heparin in patients with pulmonary compromise / pneumonia / SARS associated with COVID-19, laboratory with marked inflammation parameters, and prothrombotic state secondary to it (Fibrinogen, Ferritin and / or elevated D-Dimer) , from admission to hospitalization.

The combination of inhalation heparin combined with prophylactic doses of LMWH could reduce the progression to severe forms of the disease, and consequently the need for intensive care units and mechanical ventilation.

Conditions

Interventions

DRUG

Heparin sodium

Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours

DRUG

Enoxaparin

Subcutaneous Enoxaparine every 24 hours

Sponsors & Collaborators

  • Clinica San Camilo, Argentina

    lead OTHER

Principal Investigators

  • ALICIA B VILASECA, DR · CLINICA SAN CAMILO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-10-30
Completion
2021-06-01

Countries

  • Argentina

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530578 on ClinicalTrials.gov